- Prothena is a $2.25bn market cap biotech with a unique, epitope targeting approach to drug development.
- The company has resurrected its AL Amyloidosis drug Birtamimab and has a pivotal trial ongoing in high risk patients.
- Prothena has 3 major pharmaceutical partners - Roche in Parkinson's, BMY in Alzheimer's, and Novo Nordisk in ATTR amyloidosis.
- The company could earn billions in milestone payments over the next few years, and may become profitable in FY21.
- Prothena has its own Alzheimer's opportunities also, and all things considered, its shares look undervalued relative to its assets, addressable markets, and partnerships.
For further details see:
Prothena: Underrated Player In Alzheimer's And Parkinson's Close To Securing First Drug Approval